2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1326 Safety and efficacy of apixaban and rivaroxaban in pediatric patients with renal disease

Vito Galati, MD, Amanda Sankar, MD2, Sarah O'Brien I, MD3, Bryce Kerlin, MD4, Cassandra Rush5, Rikeenkumar Dhaduk, MPH6, Vilmarie Rodriguez, MD7
2 Nationwide Children's Hospital, Columbus, Ohio, United States
3 Nationwide Children's Hospital, Columbus, Ohio, United States
4 Nationwide Children's Hospital, Columbus, Ohio, United States
5 Nationwide Children's Hospital, Columbus, Ohio, United States
6 Nationwide Children's Hospital, Columbus, Ohio, United States

Direct oral anticoagulants (DOACs) have been shown to be non-inferior in safety and efficacy when compared to standard anticoagulation (low molecular weight heparin and warfarin) in pediatric venous thromboembolic disease (VTE) therapy.  Several reports in the adult literature support the safety and efficacy of apixaban for VTE therapy and prevention in renal disease including end stage kidney disease (ESKD). Rivaroxaban dose reductions are recommended with severe renal disease (<15 ml/min CrCl). Our institution has increasingly used apixaban and rivaroxaban in pediatric patients with renal disease for primary and secondary VTE prevention and currently there is no literature supporting the safety and efficacy of this approach for children; thus, we retrospectively reviewed the use of apixaban and rivaroxaban in the pediatric population with renal dysfunction and ESKD.

Following institutional review board approval, patients receiving DOACs were identified by review of outpatient apixaban and rivaroxaban prescriptions from 1/1/2019–1/1/2024.  Renal disease was confirmed by retrospective chart review calculation of the estimated glomerular filtration rate (eGFR) using the eGFR U25 calculator. Patients were eligible for this study if ≤21 years of age. Renal disease included acute kidney injury (AKI), chronic kidney disease (eGFR 60-89 mL/min/1.73m2 with evidence of structural damage or markers of renal dysfunction, eGFR <60mL/min/1.73m2), or patients with ESKD (eGFR <15 or the need for renal replacement therapy: dialysis or renal transplantation). Patients’ demographic and clinical data were collected including stages of renal disease, anticoagulant used, dosing, duration, bleeding and thrombosis outcomes. Descriptive statistics were used to summarize data.  95% CI = Clopper-Pearson exact binomial and p-value = Fisher's exact test was used for comparison of major/CRNM bleeding events and thrombosis recurrence events among those with ESKD and non-ESKD. Our objectives were: 1: Evaluate the safety of apixaban and rivaroxaban in patients with renal disease as defined by the International Society for Thrombosis and Haemostasis bleedingclassification system; 2: Evaluate the efficacy in prevention and/or treatment of VTE, defined by complete or partial resolution, stable disease, progression of known thrombus, or thrombosis recurrence.   

Nineteen patients with renal disease were identified with a median age at anticoagulation initiation of 15 years (range 1-21) with 57.4% (11/19) females. Median duration of anticoagulation was 145 days (range 12-2206). The median eGFR was 53 ml/min/1.73m2 (range 4.5-88.8). Fifteen patients received apixaban and four rivaroxaban: ESKD-26.3% (5/19), AKI- 21.1% (n=4/19) and CKD-52.6% (n=10/19). All patients with ESKD received apixaban.   Apixaban was used for the treatment of deep vein thrombosis (DVT) in 53.3% (n=8/15), pulmonary embolism (PE) 20% (n=3/15) and primary VTE prevention in 26.7% (n=4/15). Rivaroxaban was used for the treatment of DVT in 75% (n=3/4) and PE in 25% (n=1/4). Overall thrombus response (complete or partial resolution) was achieved in 80% (n=12/15) and stable thrombosis in 20% (n=3/15). Thrombus recurrence occurred in 26% (n=4/15; 3=CKD; 1=ESKD): apixaban (n=1 prophylactic/reduced dosing and n=2 on treatment dosing) and rivaroxaban (one patient on prophylactic/reduced doses).  No major bleeding occurred in any group with only one CRNMB event in a patient with ESKD on apixaban (menorrhagia).  Comparison of bleeding events among ESKD (95% CI 0.5-71.6) versus non-ESKD (95% CI: 0-30.8) was not statistically significant (Fisher exact p=0.33).  Thrombus recurrence among those with ESKD (95% CI: 0.5-71.6) and non-ESKD (95% CI: 2.5-55.6) was not statistically significant (Fisher exact p=1).

In conclusion, the use of apixaban and rivaroxaban in pediatric patients with renal disease appears to be safe with only one CRNM bleeding event.  Thrombus recurrence was not different among patients with ESKD and those without ESKD who were prescribed a direct oral Xa inhibitor.  Larger studies assessing the safety and efficacy of DOACs in pediatric renal disease are needed to establish anticoagulation dosing and monitoring recommendations in this pediatric population.

Vilmarie Rodriguez, MD: No relevant conflicts of interest to declare.